Molecular markers for prostatic cancer

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 2, 2010, Pages 641-656

  Castelli, Tommaso ^a   Cimino, Sebastiano ^a   Magno, Carlo ^a   Morgia, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

DNA biomarkers; EPCA; Markers; Neuroendocrine markers; PCA3; Prostate antigens; Prostate cancer; PSA; PSMA; Review

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; CHROMOGRANIN A; ENOLASE; ISOMERASE; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TUMOR MARKER;

BLOOD; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; HUMAN; MALE; PROSTATE TUMOR; PROTEOMICS; REVIEW;

CHROMOGRANIN A; EPIGENESIS, GENETIC; GENETIC MARKERS; HUMANS; MALE; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEOMICS; RACEMASES AND EPIMERASES; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954512997     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. P. Boyle, J. Ferlay: Cancer incidence and mortality in Europe 2004. Ann. Oncol., 16, 481-5 (2005)
2. A. Heidenreich, G. Aus, M. Bolla: European Association of Urology. EAU Guidelines on prostate cancer. Eur. Urol., 53, 68-80 (2008) (Pubitemid 350166735)
3. HB. Carter, A. Kettermann, L. Ferrucci, P. Landis, EJ. Metter: Prostate-specific antigen velocity risk count assessment: a new concept for detection of life threatening prostate cancer during window of curability. Urology, 70, 685-90 (2007) (Pubitemid 350030209)
4. M. C. Wang, L. D. Papsidero, T. M. Chu: Prostatespecific antigen, p30, gamma-seminoprotein, and E1. Prostate, 24, 107 (1994)
5. J. Schaller, K. Akiyama, R. Tsuda, M. Hara, T. Marti, E. Rickli: Isolation, characterization and amino acid sequence of g-seminoprotein, a glycoprotein from human seminal plasma. Eur. J. Biochem., 170, 110-120 (1987)
6. A. Lundwall, H. Lilja: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett., 214, 317-322 (1987) (Pubitemid 17085741)
7. P. Henttu, P. Viliko: cDNA coding for the entire prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem. Biophys. Res. Comm., 160, 903-910 (1989) (Pubitemid 19140605)
8. M. P. M. Q. van Gils, U. H. Stenman: Innovations in Serum and Urine Markers in Prostate Cancer. Current European Research in the P-Mark Project. Eur. Urol., 48, 1031-1034 (2005)
9. J. A. Antenor, M. Han, K. A Roehl, R. B. Nadler, W. J. Catalona: Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J. Urol., 172, 90 (2004).
10. I. M. Thompson, D. P. Ankerst, C. Chi, M. S. Lucia, P. J. Goodman, JJ. Crowley: Operating characteristics of prostate specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA, 294, 66 (2005).
11. J. Fang: Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology, 58, 411-6 (2001). (Pubitemid 32816360)
12. S. Loeb: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology, 67, 316-20 (2006). (Pubitemid 43189848)
13. I. M. Thompson, D. K. Pauler, P. J. Goodman: Prevalence of prostate cancer among men with a prostatespecific antigen level < or = 4.0 ng per millilitre. N. Engl. J. Med., 350, 2239-46 (2004).
14. H. Lilja, D. Ulmert, T. Bjö rk: Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J. Clin. Oncol., 25, 431-6 (2007). (Pubitemid 350002992)
15. A. J. Vickers, D. Ulmert, A. M. Serio: The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int. J. Cancer, 121, 2212-7 (2007). (Pubitemid 47585600)
16. I. M. Thompson, D. K. Pauler, P. J. Goodman, C. M. Tangen, M. S. Lucia, H. L. Parnes: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med., 350, 2239 (2004).
17. H. B. Carter, J. D. Pearson, E. J. Metter, L. J. Brant, D. W. Chan, R. Andres: Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA, 267, 2215 (1992).
18. M. C. Benson, I. S. Whang, C. A. Olsson, D. J. McMahon, W. H. Cooner: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., 147, 817 (1992).
19. J. E. Oesterling, S. J. Jacobsen, W. H. Cooner.: The use of age specific reference ranges for serum prostate specific antigen in men 60 years old or older. J. Urol., 153, 1160 (1995).
20. H. P. Schmid: Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. Cancer Surv., 23, 157. (1995)
21. H. B. Carter, C. H. Morrell, J. D. Pearson: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res., 52, 3323-8 (1992).
22. S. Loeb, K. A. Roehl, W. J. Catalona, R. B. Nadler: PSA velocity threshold for predicting prostate cancer in young men. J. Urol., 177, 1745-8 (2007).
23. I. M. Thompson, C. Chi, D. P. Ankerst: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J. Natl. Cancer Inst., 98, 1128-33 (2006). (Pubitemid 44288787)
24. C. Stephan, M. Klaas, C. Muller, D. Schnorr, S. A. Loening, K. Jung: Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin. Chem., 52, 59-64 (2006). (Pubitemid 43032467)
25. G. Soletormos, A. Semjonow, P. E. Sibley: Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin. Chem., 51, 1342-1351 (2005). (Pubitemid 41060864)
26. L. Bruun, C. Becker, J. Hugosson, H. Lilja, A. Christensson: Assessment of intra-individual variation in prostatespecific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate, 65, 216-21 (2005). (Pubitemid 41443726)
27. A. V. D'Amico, M. H. Chen, K. A. Roehl, W. J. Catalona: Preoperative PSAvelocity and the risk of death fromprostate cancer after radical prostatectomy. N. Engl. J. Med., 351, 125-35 (2004).
28. D. A. Patel, Jr J. C. Presti, J. E. McNeal, H. Gill, J. D. Brooks, C. R. King: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J. Clin. Oncol., 23, 6157-62 (2005).
29. M. C. Benson, I. S. Whang, A. Pantuck: Prostate specific antigen density. a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., 147, 815-6 (1992).
30. C. H. Bangma, R. Kranse, B. G. Blijenberg, F. H. Schroder: The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology, 46, 773-8 (1995).
31. C. Mettlin, P. J. Littrup, R. A. Kane: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer, 74, 1615-20 (1994). (Pubitemid 24302984)
32. W. J. Catalona, J. P. Richie, J. B. deKernion: Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol., 152, 2031-6 (1994). (Pubitemid 24354721)
33. B. Djavan, A. R. Zlotta, G. Byttebier: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J. Urol., 160, 411-8 (1998).
34. D. W. Lin, M. H. Gold, S. Ransom, W. J. Ellis, M. K. Brawer: Transition zone prostate specific antigen density. lack of use in prediction of prostatic carcinoma. J. Urol., 160, 77-81 (1998).
35. J. E. Oesterling, S. J. Jacobsen, C. G. Chute: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270, 860-4 (1993). (Pubitemid 23234116)
36. T. J. Jr Bassler, R. Orozco, I. C. Bassler, G. J. O'Dowd, T. A. Stamey: Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology, 52, 1064-9 (1998). (Pubitemid 28533377)
37. R. Etzioni, Y. Shen, J. C. Petteway, M. K. Brawer: Agespecific prostate-specific antigen: a reassessment. Prostate Suppl., 7, 70-7 (1996).
38. I. M. Thompson, D. P. Ankerst, C. Chi, P. J. Goodman, C. M. Tangen, M. S. Lucia l: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst., 98, 529 (2006).
39. W. J. Catalona, A. W. Partin, K. M. Slawin, M. K. Brawer, R. C. Flanigan, A. Patel: Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279, 1542 (1998).
40. A. W. Partin, M. K. Brawer, G. Bartsch, W. Horninger, S. S. Taneja, H. Lepor: Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J. Urol., 170, 178 (2003).
41. S. D. Mikolajczyk, L. S. Marks, A. W. Partin, H. G. Rittenhouse: Free prostate-specific antigen in serum is becoming more complex. Urology, 59, 797-802 (2002). (Pubitemid 34522163)
42. L. J. Sokoll, D. W. Chan, S. D. Mikolajczyk: Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology, 61, 274-6 (2003). (Pubitemid 36206515)
43. W. J. Catalona, G. Bartsch, H. G. Rittenhouse: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2-4 ng/ml. J. Urol., 170, 2181-5 (2003). (Pubitemid 37413952)
44. W. J. Catalona, G. Bartsch, H. G. Rittenhouse: Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2-4 ng/ml prostate specific antigen. J. Urol., 171, 2239-44 (2004). (Pubitemid 38625443)
45. S. D. Mikolajczyk, L. S. Millar, T. J. Wang: 'BPSA', a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology, 55, 41-5 (2000). (Pubitemid 30050755)
46. E. I. Canto, H. Singh, S. F. Shariat: Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology, 63, 905-10 (2004). (Pubitemid 38596676)
47. T. Steuber, P. Nurmikko: Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J. Urol., 169(1), 295 (2003).
48. H. Lilja: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest., 76, 1899-1903 (1985). (Pubitemid 16196061)
49. P. Chapdelaine, G. Paradis, R. R. Tremblay, J. Y Dube: High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett., 236, 205-208. (1988)
50. H. G. Rittenhouse, D Tindall, G. G. Klee, CY-F. Young, D. Bostwick, M. M. Saedi, L. Grauer, S. Mikolajczyk, J. Finlay, K. Kuus-Reichel: Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA, in Murphy GP, and Khoury S (Eds): Proceedings of the First International Consultation on Prostate Cancer, June 1996, Monaco. Jersey, Channel Islands, Scientific Communication International Ltd (1997).
51. M. C. Charlesworth, CY-E. Young, G. G. Klee, M. S. Saedi, S. D. Mikolajczyk, J. A. Finlay, D. J. Tindall: Detection of a prostate-specific protein, human glandular kallikrein 2 (hK2), in sera of patients with elevated prostate specific antigen levels. Urology (1997).
52. H. Lilja: Structure, function and regulation of the enzyme activity of prostate-specific antigen. World J. Urol., 11, 188-191 (1993).
53. C. Y-F. Young, P. E. Andrews, B. T. Montgomery, D. J. Tindall: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry, 31, 818-824 (1992)
54. P. Chapdelaine, G. Paradis, R. R. Tremblay, J. Y Dube: High level of expression in the prostate of a human glandular kallikrein mRNA related to prostatespecific antigen. FEBS Lett., 236, 205-208. (1988)
55. P. Murtha, D. J. Tindall, C. Y. Young: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry, 32, 6459-6464 (1993). (Pubitemid 23208830)
56. C. Becker, T. Piironen, K. Pettersson, J. Hugosson, H. Lilja: Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/ml or greater. Urology, 55, 694-699 (2000)
57. A. Haese, M. Graefen, T. Steuber, C. Becker, K. Pettersson, T. Piironen: Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate, 49, 101-109 (2001) (Pubitemid 32937805)
58. C. Becker, T. Piironen, K. Pettersson, T. Bjork, K. J. Wojno, J. E. Oesterling: Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J. Urol., 163, 311-316 (2000).
59. A. W. Partin, W. J. Catalona, J. A. Finlay, C. Darte, D. J. Tindall, CYF Young: Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology, 54, 839-845 (1999) (Pubitemid 29505583)
60. R. K. Nam, E. P. Diamandis, A. Toi, J. Trachtenberg, A. Magklara, A. Scorilas: Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J. Clin. Oncol., 18, 1036-1042 (2000). (Pubitemid 30123780)
61. C. Becker C, T. Piironen, K. Pettersson, J. Hugosson, H. Lilja: Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J. Urol., 170(4 Part 1), 1169-1174 (2003). (Pubitemid 37108105)
62. M. J. Roobol, H. G. Lilja, F. H. Schroeder: Use of total PSA, free PSA, %fPSA, and hK2 measurements to predict occurrence of prostate cancer at biopsy, ERSPC Rotterdam. J. Urol., AUA Annual Meeting 2007, 177(No. 4, Suppl): Abstract 1612.
63. A. Haese, M. Graefen, C. Becker, J. Noldus, J. Katz, I. Cagiannos: The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate, 54, 181-186 (2003) (Pubitemid 36120315)
64. T. Steuber, A. J. Vickers, A. Haese, C. Becker, K. Pettersson, F. K. Chun: Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int. J. Cancer, 118, 1234-1240 (2006). (Pubitemid 43185611)
65. R. Korets R, A. M. Serio, S. Wenske, A. J. Vickers, V. Vaisanen, M. Fleisher: Longitudinal evaluation of molecular PSA isoforms and human glandular kallikrein 2 in predicting biochemical failure following radical prostatectomy. J Urol, AUA Annual Meeting, 177(No. 4, Suppl), Abstract 1607 (2007).
66. T. Steuber, A. J. Vickers, A. M. Serio, V. Vaisanen, A. Haese, K. Pettersson: Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin. Chem., 53, 233-240 (2007). (Pubitemid 46338267)
67. C. Jeronimo, H. Usadel, R. Henrique: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst., 93, 1747-1752 (2001). (Pubitemid 33130264)
68. C. Goessl, H. Krause, M. Muller: Fluorescent methylation-specific polymerase chain reaction for DNA based detection of prostate cancer in bodily fluids. Cancer Res., 60, 5941-5945 (2000).
69. M. L. Gonzalgo, M. Nakayama, S. M. Lee: Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology, 63, 414-418 (2004). (Pubitemid 38234457)
70. S. V. Harden, H. Sanderson, S. N. Goodman, A. A. Partin, P. C. Walsh, J. I. Epstein: Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl. Cancer Inst, 95, 1634 (2003).
71. C. Goessl, M. Müller, R. Heicappell, H. Krause, M. Schostak, B. Straub: Methylation-specific PCR for detection of neoplastic DNA in biopsy washings. J. Pathol., 196, 331 (2002).
72. L. E. Crocitto, D. Korns, L. Kretzner, T. Shevchuk, S. L. Blair, T. G. Wilson: Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology, 64, 821 (2004).
73. C. Goessl, M. Muller, R. Heicappell, H. Krause, B. Straub, M. Schrader: DNA-based detection of prostate cancer in urine after prostatic massage. Urology, 58, 335.18 (2001).
74. M. O. Hoque, O. Topaloglu, S. Begum: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol., 23, 6569-6575 (2005). (Pubitemid 46190250)
75. M. Roupret, V. Hupertan, D. R. Yates: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res., 13, 1720-1725 (2007). (Pubitemid 46952937)
76. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644 (2005).
77. F. Demichelis, K. Fall, S. Perner: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogen, 26, 4596-4599.
78. Erratum in: 26, 5692 (2007).
79. B. Laxman, S. A. Tomlins, R. Mehra: Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia, 8, 885-888 (2006).
80. M. J. Bussemakers, A.van Bokhoven, G. W. Verhaegh, F. P. Smit, H. F. Karthaus, J. A. Schalken, F. M. Debruyne, N. Ru, W. B. Isaacs: DD3: a new prostate-specific gene, highly over expressed in prostate cancer. Cancer Res., 59, 5975-9 (1999). (Pubitemid 30004960)
81. L. S. Marks, Y. Fradet, I. L. Deras: PCA3 molecular urine assays for prostate cancer in men undergoing repeat biopsy. Urology, 69, 532-5 (2007). (Pubitemid 46428401)
82. D. Hessels, M. T. Klein Gunnewiek, I. van Oort: DD3 PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol., 44, 8-16 (2003). (Pubitemid 36741368)
83. A. Haese, A. de la Taille, H. van Poppel: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol., Epub ahead of print, (2008)
84. L. Sokoll, W. Ellis, P. Lange: A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy. Clin. Chim. Acta, 389, 1-6 (2008).
85. J. Groskopf, S. M. Aubin, I. L. Deras: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem., 52, 1089-95 (2006). (Pubitemid 43794421)
86. M. P. van Gils, D. Hessels, O. van Hooij: The timeresolved fluorescence based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res., 13, 939-43 (2007). (Pubitemid 46340370)
87. Z. Jiang, B. A. Woda, K. L. Rock, Y. Xu, L. Savas, A. Khan: P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol., 25, 1397-404 (2001). (Pubitemid 33022055)
88. M. A. Rubin, M. Zhou, S. M. Dhanasekaran, S. Varambally, T. R. Barrette, M. G. Sanda: Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287, 1662-70 (2002). (Pubitemid 34289218)
89. J. Luo, S. Zha, W. R. Gage, T. A. Dunn, J. L. Hicks, C. J. Bennett: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res., 62, 2220-6 (2002). (Pubitemid 34411693)
90. E. Giovannucci, E. B. Rimm, G. A. Colditz, M. J. Stampfer, A. Ascherio, C. C. Chute: A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst., 85, 1571-9 (1993). (Pubitemid 23304685)
91. C. L. Hsieh, I. Oakley-Girvan, R. R. Balise, J. Halpern, R. P. Gallagher, A. H. Wu: A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am. J. Hum. Genet., 69, 148-58 (2001). (Pubitemid 32614027)
92. F. Wiklund, E. M. Gillanders, J. A. Albertus, A. Bergh, J. E. Damber, M. Emanuelsson: Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate, 57, 290-7 (2003). (Pubitemid 37487074)
93. S. L. Zheng, B. L. Chang, D. A. Faith, J. R. Johnson, S. D. Isaacs, G. A. Hawkins: Sequence variants of alphamethylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res., 62, 6485-8 (2002). (Pubitemid 35364112)
94. S. Zha, S. Ferdinandusse, S. Denis, R. J. Wanders, C. M. Ewing, J. Luo: Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res., 63, 7365-76 (2003). (Pubitemid 37413478)
95. C. G. Rogers, G. Yan, S. Zha, M. L. Gonzalgo, W. B. Isaacs, J. Luo: Prostate cancer detection by urinalysis for alpha methylacyl CoA racemase protein. J. Urol., 172, 1501-1503 (2004). (Pubitemid 39249757)
96. A. Sreekumar, B. Laxman, D. Rhodes, S. Bhagavathula, D. Giacherio, D. Ghosh: Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J. Natl. Cancer Inst., 96, 834-43 (2004). (Pubitemid 38807604)
97. D. R. Rhodes, T. R. Barrette, M. A. Rubin: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res., 62, 4427-4433 (2002). (Pubitemid 34827303)
98. P. J. Zielie, J. A. Mobley, R. G. Ebb: A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J. Urol., 172, 1130-1133 (2004). (Pubitemid 39096486)
99. B. K. Zehentner, H. Secrist, X. Zhang: Detection of alpha-methylacyl- coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol. Diagn. Ther., 10, 397-403 (2006). (Pubitemid 44927054)
100. T. Xu, X. Chen, X. F. Wang, S. K. Hou, J. C. Zhu, X. D. Zhang: Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications. Beijing Da Xue Xue Bao, 36, 164-168 (2004).
101. G. P. Murphy, G. M. Kenny, H. Ragde, R. L. Wolfert, A. L. Boynton, E. H. Holmes: Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology, 51(5A Suppl), 89-97 (1998). (Pubitemid 28267884)
102. C. Marchal, M. Redondo, M. Padilla, J. Caballero, I. Rodrigo, J. Garcia: Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol, 19, 715-718 (2004). (Pubitemid 38855052)
103. R. Kurek, G. Nunez, N. Tselis, L. Konrad, T. Martin, S. Roeddiger: Prognostic value of combined 'triple'-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin. Cancer Res., 10, 5808-5814 (2004). (Pubitemid 39180959)
104. D. C. Chu, C. K. Chuang, Y. F. Liou, R. D. Tzou, H. C. Lee, C. F. Sun: The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Ann. NY Acad. Sci., 1022, 157-162 (2004).
105. W. J. Ellis, R. L. Vessella, E. Corey, E. W. Arfman, M. M. Oswin, S. Melchior: The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and follow-up of patients with prostate cancer. J. Urol., 159, 1134-1138 (1998). (Pubitemid 28172779)
106. Y. Z. Grasso, M. K. Gupta, H. S. Levin, C. D. Zippe, E. A. Klein: Combined nested RT-PCR assay for prostatespecific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res., 58, 1456-1459 (1998). (Pubitemid 28193608)
107. J. Thomas, M. Gupta, Y. Grasso, C. A. Reddy, W. D. Heston, C. Zippe: Preoperative combined nested reverse transcriptasepolymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J. Clin. Oncol., 20, 3213-3218 (2002). (Pubitemid 34831517)
108. Z. Xiao, B. L. Adam, L. H. Cazares, M. A. Clements, J. W. Davis, P. F. Schellhammer: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res., 61, 6029-6033 (2001). (Pubitemid 32762533)
109. M. L. Beckett, L. H. Cazares, A. Vlahou, P. F. Schellhammer, Jr. G. L. Wright: Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin. Cancer Res., 5, 4034-4040 (1999). (Pubitemid 30013781)
110. R. H. Getzenberg, K. J. Pienta, E. Y. Huang, D. S. Coffey: Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res., 51, 6514-20 (1991).
111. R. Dhir, B. Vietmeier, J. Arlotti: Early identification of individuals with prostate cancer in negative biopsies. J. Urol., 171, 1419-23 (2004). (Pubitemid 38365385)
112. H. Uetsuki, H. Tsunemori, R. Taoka, R. Haba, M. Ishikawa, Y. Kakehi: Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J. Urol., 174, 514-8 (2005). (Pubitemid 40981588)
113. B. Paul, R. Dhir, D. Landsittel, M. R. Hitchens, R. H. Getzenberg: Detection of prostate cancer with a bloodbased assay for early prostate cancer antigen. Cancer Res., 65, 4097-100 (2005). (Pubitemid 40775646)
114. E. S. Leman, G. W. Cannon, B. J. Trock: EPCA-2: a highly specific serum marker for prostate cancer. Urology, 69, 714-20 (2007). (Pubitemid 46574950)
115. E. F. Petricoin, D. K. Ornstein, C. P. Paweletz: Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst., 94, 1576-1578 (2002). (Pubitemid 35277282)
116. R. E. Banks, A. J. Stanley, D. A. Cairns: Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem., 51, 1637-1649 (2005). (Pubitemid 41233099)
117. E. P. Diamandis: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst., 96, 353-356 (2004). (Pubitemid 38351297)
118. K. A. Baggerly, J. S. Morris, S. R. Edmonson, K. R. Coombes: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst., 97, 307-309 (2005). (Pubitemid 40310279)
119. J. Villanueva, D. R. Shaffer, J. M. Philip: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest., 116, 271-284 (2006). (Pubitemid 43121812)
120. D. McLerran, W. E. Grizzle, Z. Feng: SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem., 54, 53-60 (2008). (Pubitemid 351182596)
121. D. McLerran, W. E. Grizzle, Z. Feng: Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem., 54, 44-52 (2008). (Pubitemid 351182595)
122. P. A. Abrahamsson: Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer, 6, 503-19 (1999).
123. S. Isshiki, K. Akakura, A. Komiya, H. Suzuki, N. Kamiya, H. Ito: Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J. Urol., 167, 512-15 (2002). (Pubitemid 34074517)
124. M. Yashi, O. Muraishi, Y. Kobayashi, A. Tokue, H. Nanjo: Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients. Prostate, 51, 84-97 (2002).
125. A. Angelsen A, U. Syversen, M. Stridsberg, O. A. Haugen, O. K. Mjolnerod, H. L. Waldum: Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate, 31, 110-17 (1997). (Pubitemid 27188140)
126. D. T. O'Connor, L. J. Deftos: Secretion of chromogranin A by peptide-producing endocrine neoplasms. N. Engl. J. Med., 314, 1145-51 (1986). (Pubitemid 16138661)
127. F. R. Nobels, D. J. Kwekkeboom, W. Coopmans: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab., 82, 2622-8 (1997). (Pubitemid 27337883)
128. N. Kimura, S. Hoshi, M. Takahashi, S. Takeha, S. Shizawa, H. Nagura. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J. Urol., 157, 565-8 (1997). (Pubitemid 27026839)
129. A. Angelsen, U. Syversen, O. A. Haugen, M. Stridsberg, O. K. Mjolnerod, H. L. Waldum: Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?. Prostate, 30, 1-6 (1997). (Pubitemid 27053534)
130. J. T. Wu, M. E. Astill, G. H. Liu, R. A. Stephenson: Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J. Clin. Lab. Anal., 12, 20-5 (1998). (Pubitemid 28079998)
131. D. Kadmon, T. C. Thompson, G. R. Lynch, P. T. Scardino: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol., 146, 358-61 (1991).
132. M. Tarle, S. Frkovic-Grazio, I. Kraljic, K. Kovacic: A more objective staging of advanced prostate cancer-routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate, 24, 143-8 (1994). (Pubitemid 24109595)
133. N. Kamiya, K. Akakura, H. Suzuki: Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur. Urol., 44, 309-14; discussion 314 (2003). (Pubitemid 37051698)
134. M. S. Soloway, S. W. Hardeman, D. Hickey: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195-202 (1998).
135. P. A. Di Sant'Agnese: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer, 70, 254-68 (1992).
136. Y. Miyake, T. Kodama, K. Yamaguchi: Pro-gastrinreleasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res., 54, 2136-40 (1994). (Pubitemid 24138686)
137. F. Cuttitta, D. N. Carney, J. Mulshine: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature, 316, 823-6 (1985). (Pubitemid 15003742)
138. K. Yamaguchi, K. Abe, T. Kameya: Production and molecular size heterogeneity of immunoreactive gastrinreleasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res., 43, 3932-9 (1983). (Pubitemid 13077727)
139. O. Nagakawa, Y. Furuya, Y. Fujiuchi, H. Fuse: Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma. Urology, 60, 527-30 (2002). (Pubitemid 35292198)
140. M. Yashi, S. Ishikawa, A. Tokue: Serum pro-gastrinreleasing peptide (31-98) in prostatic diseases. Urology, 62, 198-9 author reply 199 (2003). (Pubitemid 36802115)